Search
Reviva Pharmaceuticals Holdings Inc
RVPHAdd to Watchlist
0.352USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.65MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-05-13The current earnings forecast score of Reviva Pharmaceuticals Holdings Inc is 7.67, ranking 278 out of 383 in the Biotechnology & Medical Research industry. The average price target is 3.50, with a high of 16.00 and a low of 2.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
17.500
Target Price
+4870.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Reviva Pharmaceuticals Holdings Inc
RVPH
1
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Reviva Pharmaceuticals Holdings Inc's price target?
Analysts forecast that Reviva Pharmaceuticals Holdings Inc's price target is USD 3.50, with the highest forecast at USD 16.00 and the lowest forecast at USD 2.00.
How have Reviva Pharmaceuticals Holdings IncRVPH's recent earnings per share performed?
The market expectation was USD -0.46, while Reviva Pharmaceuticals Holdings IncRVPH's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Reviva Pharmaceuticals Holdings Inc?
Based on the ratings of Reviva Pharmaceuticals Holdings Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.